53. Sjogren syndrome Clinical trials / Disease details

Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04397107 (ClinicalTrials.gov)	August 15, 2020	6/5/2020	The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases	The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis)	Systemic Lupus Erythematosus	Drug: IL-2	The First Hospital of Jilin University	NULL	Recruiting	N/A	17 Years	All	46	N/A	China
2	ChiCTR-INR-17011220	2017-04-24	2017-04-23	The Efficacy and Safety of Low Dose IL-2Therapy in Chinese patients with primary Sjogren's syndrome	The Efficacy and Safety of Low Dose IL-2Therapy in Chinese patients with primary Sjogren's syndrome	primary Sj?gren’s syndrome	Ll-2 group:IL-2 treatment; non IL-2 group:conventional treatment;	the Second Hospital of Shanxi Medical University	NULL	Recruiting			Both	Ll-2 group:90; non IL-2 group:90;		China
3	NCT02464319 (ClinicalTrials.gov)	June 1, 2015	30/5/2015	A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome	Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Drug: hrIL-2 active;Drug: hrIL-2 placebo	Peking University People's Hospital	Monash University;Beijing ShuangLu Pharmaceutical Co., Ltd.	Completed	18 Years	65 Years	All	60	Phase 2	China